Clinical Trial ProgressBrainStorm announced new survival data from the Expanded Access Program for NurOwn cell therapy, showing that 90% of patients survived more than five years, compared to the average life expectancy for ALS patients of 2-5 years.
Manufacturing PartnershipsThe strategic collaboration with Minaris Advanced Therapies enhances US-based manufacturing capabilities and brings the scalability needed for NurOwn's complex autologous cell therapy.
Regulatory ApprovalThe FDA's recent leadership changes and new pathways for drugs to treat rare and debilitating diseases are viewed as more favorable for therapies like stem cells.